

# Myeloma Pathways: Multiple Myeloma

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

ICD-10 Code: \_\_\_\_\_ Pathology: \_\_\_\_\_

Stage:  New diagnosis  Relapse

Line of Treatment:  First Line  Second Line  Third Line  Third Line+  Maintenance

ECOG Performance Status:  0  1  2  3  4

Biomarker:

Transplant candidate  Non-transplant candidate

## Primary/ First line of therapy (1<sup>st</sup> line) | Transplant candidates

VRD/VDR: bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone

## Primary/ First line of therapy (1<sup>st</sup> line) | Ineligible for transplant

CyBORd or VDC: bortezomib (Velcade), cyclophosphamide (Cytoxan), and dexamethasone

R-dex: lenalidomide (Revlimid) and low-dose dexamethasone

VRD/VDR: bortezomib (Velcade), lenalidomide (Revlimid) and dexamethasone

VD: bortezomib (Velcade) and dexamethasone

## Maintenance therapy | Post-transplant

Lenalidomide (Revlimid)

## Relapsed disease | Second and subsequent lines of therapy (2<sup>nd</sup> line+)

CRd or KRd: carfilzomib (Kyprolis), lenalidomide (Revlimid) and dexamethasone

DRD: daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone

DVD: daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone

## Relapsed disease | Third and subsequent lines of therapy (3<sup>rd</sup> line+)

Daratumumab (Darzalex)

Elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.